Amylyx Pharmaceuticals IPO

1/7/2022

IPO

$190,000,000

We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, to fund: (i) the regulatory approval process and pre-commercial launch, production of and, if approved, commercial launch activities for AMX0035 for the treatment of ALS; (ii) the completion of our ongoing Phase 3 PHOENIX clinical trial for the treatment of amyotrophic lateral sclerosis, or ALS; (iii) the development and expansion of our pipeline to address other neurodegenerative indications, and for formulations and derivatives of AMX0035; and (iv) working capital and other general corporate activities, including the continued build out of our organization.

Publicly-held

Biopharmaceutical

43 Thorndike St.
Cambridge, MA 02141
USA

Undisclosed

Amylyx is an IND-enabling stage biopharmaceutical company dedicated to providing innovative, disease-modifying solutions for neurodegenerative diseases. We have a highly creative and motivated team focused on streamlined clinical development and drug discovery.